Research company Aptahem has announced the final outcome in the company’s rights issue, which was subscribed to approximately 23.7 percent. The issue provides the company with approximately SEK 3.15 million before issue costs after set-off of debt of approximately SEK 0.15 million."We want to extend a big thank you to our shareholders for your continued support and trust. With this behind us, we now continue our focused work to drive Apta-1 forward and strengthen our strategic initiatives ahead of the next development phase, with a particular focus on advancing our partnership discussions. Our long-term goal is to address the major medical need in sepsis and related diseases by contributing to new treatment options for patients who currently lack effective alternatives", says CEO Mikael Lindstam. Of the total outcome, approximately 22.1 percent was subscribed with the support of subscription rights and an additional approximately 1.6 percent without the support of subscription rights. The number of shares increases by approximately 5 million to 25.9 million, corresponding to dilution of approximately 19.1 percent for shareholders who did not participate. Trading in the new shares is expected to begin around week 21.